News
NLSP
1.950
-18.07%
-0.430
NLS Pharmaceutics and Kadimastem Advance Diabetes Treatment with FDA Submission
TipRanks · 2d ago
NLS Pharmaceutics, Kadimastem submit request for FDA pre-IND meeting
TipRanks · 2d ago
NLS Pharmaceutics Plans Capital Increase at Extraordinary Shareholders’ Meeting
TipRanks · 4d ago
Weekly Report: what happened at NLSP last week (1209-1213)?
Weekly Report · 5d ago
NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans
TipRanks · 12/11 17:02
NLS Pharmaceutics expects to close Kadimastem merger by end of January
TipRanks · 12/11 12:45
Which subsectors to own and which to avoid – Wolfe Research
Seeking Alpha · 12/10 18:33
Weekly Report: what happened at NLSP last week (1202-1206)?
Weekly Report · 12/09 09:57
NLS Pharmaceutics Offers New Investment Opportunities
TipRanks · 12/04 21:27
NLS Pharmaceutics announces pricing of private placement of up to $1M
Seeking Alpha · 12/04 19:13
NLS Pharmaceutics Announces Pricing Of A Private Placement Offering Consisting Of The Issuance And Sale Of Up To 322,580 Common Shares Only At A Purchase Price Of $3.10 Per Common Share, For Aggregate Gross Proceeds Of Up To $1M
Benzinga · 12/04 18:16
NLS Pharmaceutics Unveils Promising Data for New Treatments
TipRanks · 12/03 13:28
NLS Pharmaceutics announces preclinical data on DOXA platform
TipRanks · 12/03 12:50
NLS Pharmaceutics Says Preclinical Data Demonstrate The Potential Of Its Dual Orexin Receptor Agonist Platform, An Investigational New Drug Application Is Planned For 2026-2027
Benzinga · 12/03 12:46
Weekly Report: what happened at NLSP last week (1125-1129)?
Weekly Report · 12/02 09:57
Weekly Report: what happened at NLSP last week (1118-1122)?
Weekly Report · 11/25 09:54
NLS Pharmaceutics Unveils Promising Narcolepsy Treatment
TipRanks · 11/18 13:59
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2
TipRanks · 11/18 12:46
Weekly Report: what happened at NLSP last week (1111-1115)?
Weekly Report · 11/18 09:52
NLS Pharmaceutics AG Announces Share Capital Expansion
TipRanks · 11/15 22:30
More
Webull provides a variety of real-time NLSP stock news. You can receive the latest news about Nls Pharmaceutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NLSP
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.